Publications by authors named "M S Los"

Biomimetic natural biomaterial (BNBM) nanocomposite scaffolds for bone replacement can reduce the rate of implant failure and the associated risks of post-surgical complications for patients. Traditional bone implants, like allografts, and autografts, have limitations, such as donor site morbidity and potential patient inflammation. Over two million bone transplant procedures are performed yearly, and success varies depending on the material used.

View Article and Find Full Text PDF

Aim: The miRNA cargo of plasma extracellular vesicles (EVs) is commonly studied for its biomarker potential. However, isolation of EVs from human plasma is challenging. Although size-exclusion chromatography (SEC) is commonly used to isolate plasma EVs, SEC does not completely separate EVs from other miRNA carriers such as cells, lipoproteins, and proteins.

View Article and Find Full Text PDF

Introduction: Adjuvant chemotherapy improves survival in patients with resected pancreatic ductal adenocarcinoma (PDAC). The decision to initiate chemotherapy involves both patient and physician factors, decision-specific criteria, and contextual considerations. This study aimed to assess medical oncologists' views on adjuvant chemotherapy following pancreatic resection for PDAC.

View Article and Find Full Text PDF
Article Synopsis
  • Prostate cancer is a major public health concern, and this meta-analysis investigates the link between diabetes and its risk.
  • A review of 43 studies, totaling nearly 3.75 million patients, shows that diabetes may actually be associated with a lower risk of developing prostate cancer.
  • However, patients with a family history of the disease have a heightened risk, suggesting genetic factors play a role.
View Article and Find Full Text PDF

Chronic diseases such as cancer, autoimmunity, and organ failure currently depend on conventional pharmaceutical treatment, which may cause detrimental side effects in the long term. In this regard, cell-based therapy has emerged as a suitable alternative for treating these chronic diseases. Transdifferentiation technologies have evolved as a suitable therapeutic alternative that converts one differentiated somatic cell into another phenotype by using transcription factors (TFs), small molecules, or small, single-stranded, non-coding RNA molecules (miRNA).

View Article and Find Full Text PDF